ID Title Translation language Translation source Changed Translation outdated
6971 Roles and Responsibilities of MO-PHI under the 100 Days Campaign English Not specified Off
6970 Goal and Key Strategies of the 100 Days Campaign English Not specified Off
6969 100 Days Campaign English Not specified Off
6968 Key Strategies of the 100 Days Campaign English Not specified Off
6967 Introduction to 100 Days Campaign English Not specified Off
6961 2024 Updates in DR-TB Management English Not specified Off
6959 Management of ADRs - DR-TB Treatment English Not specified Off
6957 Management DR-TB in Special Situations - People with anemia English Not specified Off
6956 Principles of Switching to BPal from Shorter Oral Regimen English Not specified Off
6955 Management of DR-TB Treatment interruptions English Not specified Off
6952 Ambulatory care for DR-TB patients English Not specified Off
6951 Reconstitution of PwB for BPaLM regimen English Not specified Off
6949 Scenarios for deciding for DR-TB Regimen English Not specified Off
6945 Management DR-TB in Special Situations English Not specified Off
6943 Management DR-TB in Special Situations - People with Diabetes Mellitus English Not specified Off
6941 Refreshing BDQ course after switching between regimens English Not specified Off
6940 Management DR-TB in Special Situations - People with Liver disease English Not specified Off
6938 Principles of Switching from BpalL/ Shorter Oral Regimen to Longer Oral Regimen English Not specified Off
6937 Management DR-TB in Special Situations - different age groups English Not specified Off
6935 Management of DR-TB in people living with HIV English Not specified Off
6933 TB Disease Severity considerations for Management English Not specified Off
6932 Regimen Modification of Shorter Oral MDR/RR regimen containing Bdq and Lnz English Not specified Off
6931 Follow-up monitoring of modified shorter oral MDR/RR-TB regimen with Lzd English Not specified Off
6928 Issue of BPaLM regimen PwBs English Not specified Off
6927 Packaging of BPaLM regimen and PwB English Not specified Off
6926 Discordance resolution in RR between LPA and NAAT English Not specified Off
6925 Follow-up monitoring of BPaLM English Not specified Off
6924 Screening of patients on BPaLM regimen for Linezolid toxicity English Not specified Off
6923 Extension criterion for BPaLM regimen English Not specified Off
6922 Implementation Consideration for BPaLM regimen English Not specified Off
6921 Regimen modification for patients on BPaLM regimen English Not specified Off
6920 Management of BPaLM ineligible patients English Not specified Off
6919 Overview of Treatment Course for patients on BPaLM regimen English Not specified Off
6918 Pregnancy and Lactation English Not specified Off
6916 Evidence for the efficacy of BPaL regimen in DR-TB English Not specified Off
6915 Peripheral neuropathy screening tool English Not specified Off
6914 Long term follow-up for DR-TB treatment English Not specified Off
6913 Treatment initiation for MDR/RR-TB cases English Not specified Off
6912 Integrated DR-TB Algorithm English Not specified Off
6911 Peripheral Neuropathy English Not specified Off
6909 DAIDS scale for assessment of Peripheral Neuropathy English Not specified Off
6908 Rationale for continuation of Moxifloxacin in BPaLM regimen irrespective of FQ resistance English Not specified Off
6906 Newer Anti-TB Drugs: Pretomanid [Pa] English Not specified Off
6907 Relative contraindications Criteria for BPaLM English Not specified Off
6905 BPaLM regimen for DR-TB English Not specified Off
6904 2024 NTEG Recommendations for DR-TB Management English Not specified Off
6903 WHO recommendation for newer, shorter, oral regimens English Not specified Off
6902 Eligibility Criteria for BPaLM English Not specified Off
5460 Methodology for TB Mukt Panchayat Gujarati English Off
5461 Certification Process for TB Mukt Panchayat Gujarati English Off